Fully-automated platform for molecular diagnostics
Randox partners with Bosch to launch ‘Vivalytic’, the all-in-one fully automated solution for molecular diagnostics. Using Randox-patented Biochip Array Technology, Vivalytic is the easiest to use and most comprehensive multiplex PCR platform on the market. The device also supports single-plex and low-plex testing, simplifying the processes for otherwise complex laboratory test procedures. Depending on the test application, results will be delivered from 30 minutes. The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually-transmitted infections (CE and FDA pending). The Respiratory Multiplex Array simultaneously detects 22 viral and bacterial pathogens including Bordetella parapertussis – without the need for secondary or confirmatory
testing to inform clinical treatment decisions. The STI (Sexually-Transmitted Infections) array enables the detection of 10 viral, bacterial and protozoan STIs from a single urine or urogenital swab sample. Every day more than 1 million STIs are acquired and many have no symptoms or only mild ones which may not be recognized as an STI. Chlamydia trachomatis, N. gonorrhoeae, Trichomonas vaginalis, and Treponema pallidum, all of which can be detected on the biochip, are among the most common causes. Identifying these infections correctly first time reduces the misuse of antibiotics and supports their targeted use, while saving costs associated with single infection detection.
